Most Read Articles
Dr. Joseph Delano Fule Robles, 4 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
27 May 2016
TRIPLIXAM – Perindopril arginine, Indapamide, Amlodipine FC tab – Servier
01 Jul 2016
Get access to disease management charts, dosage guidelines and much more.

Rescue therapy with mycophenolate mofetil moderately effective in AIH

11 Nov 2017

Use of mycophenolate mofetil (MMF) as rescue therapy in patients with autoimmune hepatitis (AIH) appears to be well tolerated, with moderate efficacy for inducing remission, according to data from the Tapestry study. However, response rates may be lower and infection rates higher in the presence of cirrhosis.

Researchers reviewed the medical records of 105 AIH patients who received MMF after an inadequate response or intolerance to standard therapy. Data of interest were baseline demographics, liver disease characteristics, initial therapy, MMF indications, treatment outcome and side effects.

Of the patients, 98 percent were previously treated with the combination of corticosteroids and thiopurine. Indications for MMF included treatment nonresponse (40 percent) and intolerance to therapy (60 percent).

After a median treatment duration of 12 weeks, 63 (60 percent) patients achieved biochemical remission with MMF. Treatment response in the group receiving MMF due to nonresponse to previous treatment was comparable to that in the group receiving MMF due to intolerance to standard therapy (57 vs 62 percent).

However, response rates were lower among patients with cirrhosis vs those without (47 vs 66 percent; p=0.07).

Serious adverse events (AEs) were reported in three patients (2.7 percent), including one death. AEs resulted in treatment discontinuation in 10 patients (9.2 percent).

Used extensively in organ transplantation settings, MMF exerts selective antiproliferative effects on T- and B-lymphocytes by inhibiting DNA synthesis. Evidence shows that MMF is a good second-line agent for patients who fail to respond to or who cannot tolerate azathioprine. [J Clin Exp Hepatol 2014;4:221–22]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 4 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
27 May 2016
TRIPLIXAM – Perindopril arginine, Indapamide, Amlodipine FC tab – Servier
01 Jul 2016
Get access to disease management charts, dosage guidelines and much more.